Profacgen delivers a comprehensive suite of screening and profiling services designed to accelerate every phase of drug discovery, from target validation to lead optimization. Our integrated platform combines biochemical assays, cell-based functional screens, and advanced molecular profiling technologies to help you rapidly narrow large compound libraries to focused sets of promising candidates, predict potency and selectivity, and de-risk your development pipeline.
All screening campaigns are executed with rigorously validated assay protocols and high-quality reagents developed in-house, ensuring exceptional data consistency and reproducibility. Each project is supported by a dedicated manager who guides you through experimental design, execution, and data interpretation, with comprehensive reporting that includes detailed protocols, raw data, and analyzed results.
Select the service category that aligns with your discovery goals:
Access the largest class of drug targets with our comprehensive GPCR screening platform. We offer binding assays, G-protein coupling evaluation, β-arrestin recruitment, and second-messenger quantification across a broad panel of receptors, enabling full pharmacological characterization of your compounds from potency to pathway bias.
Evaluate compound interactions with voltage-gated and ligand-gated ion channels using electrophysiology and ion flux assays. Our platform supports cardiac safety profiling (hERG), pain target validation, and neurological drug discovery with high signal-to-background readouts.
Assess drug-transporter interactions with our specialized panels covering FDA-recommended transporters, monoamine transporters, and solute carrier families. Uptake and inhibition assays provide critical data for DDI liability, neuropsychiatric drug discovery, and ADMET optimization.
Target the sensory receptors that mediate temperature, touch, and pain sensation. Building on Nobel Prize-winning discoveries in somatosensation, our platform screens compounds against TRP channels, Piezo proteins, and related mechanosensitive ion channels for next-generation analgesics and sensory therapeutics.
Discover high-affinity nucleic acid ligands for your target of interest through our SELEX-based aptamer selection platform. Aptamers offer antibody-like specificity with superior stability, lower production costs, and broader target range—including small molecules, toxins, and non-immunogenic targets.
Map protein-DNA interactions and transcriptional regulatory networks with precision. Our assay portfolio includes EMSA, DNase I footprinting, and ChIP-seq, providing comprehensive data on binding affinity, sequence specificity, and genomic occupancy for your transcription factors of interest.
Achieve femtogram-level protein detection sensitivity with our SiMoA digital immunoassay platform. Thousands of times more sensitive than conventional ELISA, SiMoA enables quantification of ultra-low-abundance biomarkers in serum, plasma, urine, and other sample types for precision medicine and early disease detection.
Contact us today to discuss your screening requirements and receive a customized project proposal tailored to your targets, timeline, and budget.
Fill out this form and one of our experts will respond to you within one business day.